| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"AVITA Medical Reports Second Quarter Financial Results VALENCIA, California, August 10, 2023 — AVITA Medical, Inc. , a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the second quarter June 30, 2023. Financial Highlights and Recent Updates • Commercial revenue of $11.7 million, a 42% increase compared to $8.2 million for the same period in 2022 • Received Food and Drug Administration approval of premarket approval supplement for the use of RECELL to treat full-thickness skin defects on June 7 • Initiated commercial launch of full-thickness skin defects, along with additional eligible burn procedures, with expanded U.S. comm..." |
|
| 06/30/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/15/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer VALENCIA, Calif., June 15, 2023 and MELBOURNE, Australia, June 16, 2023 — AVITA Medical, Inc. , a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public companies. O'Toole will play a critical role in ex..." |
|
| 06/08/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/25/2023 |
424B2
| Form 424B2 - Prospectus [Rule 424(b)(2)]: |
| 04/21/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/21/2023 |
8-K
| Quarterly results |
| 03/08/2023 |
8-K
| Other Events Interactive Data |
| 03/02/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 4.6% stake in Avita Medical Inc. |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/19/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/07/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/30/2022 |
8-K
| Quarterly results |
| 09/22/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/02/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/30/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/12/2022 |
8-K
| Quarterly results |
|